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Abstract: 
Objectives: To identify SNPs associated with switching from an ACE-inhibitor to an angiotensin 
receptor blocker (ARB).  
Methods: Two cohorts of patients starting ACE-inhibitors were identified within the Rotterdam 
Study in the Netherlands and the GoDARTS study in Scotland. Cases were intolerant subjects 
who switched from an ACE-inhibitor to an ARB, controls were subjects who used ACE-inhibitors 
continuously for at least 2 years and did not switch. GWAS using an additive model was run in 
these sets and results were meta-analysed using GWAMA. 
Results: 972 cases out of 5 161 ACE-inhibitor starters were identified. 8 SNPs within 4 genes 
reached the GWAS significance level (P<5×10-8) in the meta-analysis (RBFOX3, GABRG2, SH2B1 
and MBOAT1). The strongest associated SNP was located in an intron of RBFOX3, which 
contains a RNA binding protein (rs2061538: MAF=0.16, OR=1.52[95%CI: 1.32-1.76], p=6.2x10-9). 
Conclusions: These results indicate that genetic variation in abovementioned genes may 
increase the risk of ACE-inhibitors induced adverse reactions. 
 
Keywords: ACE inhibitors, ACE-inhibitor intolerance, adverse drug reaction, cough, 
angioedema, Genome Wide Association Study. 
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Introduction: 
Angiotensin converting enzyme inhibitors (ACE-inhibitors) are one of the most frequently 
prescribed groups of medications for the management of high blood pressure, heart failure and 
renal disease [1]. While ACE-inhibitors are generally prescribed for lifetime treatment, a cohort 
study showed that 32.4% of patients halted their medication likely due to adverse drug 
reactions (ADRs) within a median 336 days follow up time [2]. The most common ACE-inhibitor 
induced ADR is a persistent, dry cough and the most severe one is life threatening angioedema 
of lips, tongue and upper airway [3]. There is evidence suggesting genetic predisposition to 
these ADRs; ACE-inhibitor induced cough occurs with higher incidence in East Asian patients 
(23%) compared with Caucasians (5–11%) [4, 5]. The ACE-inhibitor induced angioedema rate is 
higher in black patients than in white patients and angioedema patients often have affected 
relatives [6, 7]. 
The mechanism of ACE-inhibitor induced cough and angioedema is not completely understood.  
ACE-inhibitors inhibit Angiotensin I Converting Enzyme (ACE) that cleaves several target 
proteins including angiotensin I and pro-inflammatory kinins. The blood pressure modification 
takes place through angiotensin I [8].  Accumulation of these inflammatory kinins is 
hypothesized to be the main reason of ACE-inhibitor induced angioedema and cough [9, 10]. 
For two decades, multiple candidate genes studies have tested the associations between ACE-
inhibitor induced cough and genetic variation in ACE and bradykinin pathways, of which the 
insertion-deletion (I/D) variation in the ACE gene has been investigated most frequently [11-
14]. A meta-analysis of 12 such studies, did not find a statistically significant association for the 
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ACE I/D polymorphism [15]. Studies on ACE-inhibitor induced angioedema have also been 
conducted with the same approach; 3 of them found a statistically significant association 
between ACE-inhibitor induced angioedema and single nucleotide polymorphisms (SNPs) in the 
XPNPEP2 gene [16-18]. One study showed that the bradykinin receptor2 (B2) -9/+9 
polymorphism is associated with both ACE-inhibitor induced cough and angioedema [19]. 
However generally, most of the candidate gene approach studies have been difficult to 
replicate and their results should be interpreted with caution [20]. The only genome wide 
association study (GWAS) on 175 ACE-inhibitor induced angioedema cases and 489 controls 
that also used ACE-inhibitors, found no genome-wide association, which might be due to the 
small sample size [21]. For ACE-inhibitor induced cough, the only GWAS with 1 595 cases and 5 
485 controls identified genome-wide significant associations in KCNIP4 gene at chromosome 4 
(rs145489027, p=1.0x10-8) which was replicated in 2 independent populations [22].  
Based on the probable similar mechanism of ACE-inhibitor induced ADRs (cough and 
angioedema), this study aims to use a GWAS approach to identify SNPs associated with 
intolerance of ACE-inhibitors defined as switching of an ACE-inhibitor to an angiotensin 
receptor blocker (ARB) as a marker for ADRs [23].  
Methods: 
Study population: 
This study was performed in 2 separate European populations: 
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A) The Rotterdam study in the Netherlands has been described in detail previously [24, 25]. In 
summary, it is an ongoing cohort, composed of three different sub-cohorts (RS1, RS2, and 
RS3), started in 1990 in Ommoord a suburb of Rotterdam that has included 14 926 subjects 
aged 45 years or older (72.0 % of 20 744 eligible invited people). The Rotterdam Study has 
been approved by the medical ethics committee according to the Wet 
Bevolkingsonderzoek: ERGO (Population Study Act: Rotterdam Study), executed by the 
Ministry of Health, Welfare and Sports of the Netherlands. All participants gave informed 
consent to participate in the study and to obtain information from treating physicians and 
pharmacies, separately. 
B) The (Go-DARTS study) which is a genetic sub-study of The Diabetes Audit and Research 
Tayside, Scotland (DARTS) that has been described and validated in previous publications 
[26]. In summary, this project was based on linking clinical records by a patient-specific 
identifier, allowing the creation and maintenance of sophisticated regional health 
informatics systems. The DARTS project electronically followed all residents in Tayside, since 
January 1996 (n=391 274 including 7 596 individuals with diabetes) through linking the 
clinical datasets with a high degree of reliability and accuracy. Collection and analysis of 
data in DARTS and Go-DARTS was approved by the East of Scotland Research and Ethics 
Committee, in compliance with the declaration of Helsinki. 
Phenotype: 
For both study populations similar phenotype definitions were applied for cases and control 
selection: 
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Cases: Patients who switched to an ARB during ACEI treatment. 
Controls: Patients, who started ACE-inhibitors, and continued treatment for at least 2 years. 
They did not discontinue or switch their ACE-inhibitors during the follow up.  
For defining continuation, discontinuation or switching, a maximum of 6 months gap between 2 
prescription periods was considered. These definitions were validated in our previous study as 
the best marker of ACE-inhibitor induced ADRs within the prescription databases [23].  
Genotyping: 
Within the Rotterdam study a total of 12 453 subjects were genotyped with Illumina 500(+duo) 
and Illumina 610 quad and 11 496 subjects passed genotyping quality control. Exclusion criteria 
for SNPs were a call rate <98%, Hardy-Weinberg p-value <1 × 10^-6, minor allele frequency 
<0.01%, excess autosomal heterozygosity >0.336, sex mismatch and outlying identity-by-state 
clustering estimates. Data was imputed with the 1000-Genomes reference panel (phase 1, 
version 3) using MACH version 1.0.15/1.0.16.  
Within the Go-DARTS study, subjects were genotyped on the Affymetrix 6.0 (Affymetrix, Santa 
Clara, CA, USA) or Illumina HumanOmniExpress (Illumina, San Diego, CA, USA) platforms. Both 
platforms were imputed using IMPUTE2 and the 1000 Genomes reference panel. SNPs 
deviating from Hardy–Weinberg equation (P<1 × 10^−6) or with an Info Score <0.4 were 
excluded. 
Data analyses: 
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The primary single SNP tests of association were performed using logistic regression assuming 
an additive genetic model, adjusting for age and gender. PLINK v1.07 was used for the Dutch 
cohort [27] and SNPTEST-v2.5-beta was used for the Scottish cohort [28].  The fixed effect 
meta-analyses were done at both sites using the inverse variance weighting, in the Netherlands 
using METAL and Scotland using GWAMA [29, 30]. The final SNP list in the Netherlands analysis 
was filtered based on the index of heterogeneity (I 2 <60) and the number of cohorts that 
covered a SNP (more than two cohorts) [31]. The final values presented in this study are from 
the analyses in Scotland because GWAMA provides the odds ratios and does not require further 
calculations; however the consistency of the results at both sites was considered for the most 
significantly associated SNPs. Data of SNPs around the most significant gene were visualized 
using LocusZoom [32]. All other analyses were performed using SAS v9.3 (SAS Institute, Cary, 
NC, USA). R packages were used to plot the graphs. Metafor R package used for forest plot [33] 
and qqman package for Manhattan and QQ plot [34]. 
Results: 
A total of 710 cases of ACE-inhibitor intolerant patients and 3 599 tolerant controls in the 
Genetics of Diabetes Audit and Research in Tayside Scotland (Go-DARTS) population and 262 
cases and 590 controls in the population of the Rotterdam study were analysed separately and 
subsequently meta-analysed. 2004 patients from Go-DARTS population were genotyped using 
the Illumina chip (GD1) and the rest (2305 patients) were genotyped using the Affymetrix chip 
(GD2). Three sub populations within Rotterdam study, RS1, RS2 and RS3 had 630, 170 and 52 
patients respectively). In both cohorts the mean age of included patients was not statistically 
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significantly different between cases and controls. The proportion of females was significantly 
higher within cases compared to controls in both cohorts (Table 1).  
In the meta-analysis of both cohorts using multivariable regression analyses adjusting for 
gender and age, 8 SNPs located on chromosome 5 (one SNP), 6 (one SNP), 16 (one SNP) and 17 
(five SNPs) reached genome-wide significance level (P-value less than 5x10-08) (Figure 1 and 2). 
Table 2 shows the details of the most statistically significantly associated SNPs. From these 
SNPs, two were only available in the Go-DARTS population (rs192613545 and the 
insertion/deletion polymorphism on chromosome 17 position 77112502). A List of the most 
significantly associated SNPs which reached P-value of less than 10-05 in meta-analysis, is 
available in the supplement in Table 1. The most significantly associated SNP (rs2061538) was 
located within the gene RBFOX3 (RNA Binding Protein, Fox-1 Homolog (C. Elegans) 3). There 
were several other strongly associated SNPs in high linkage disequilibrium (LD) with this SNP in 
that region (Figure 3A). The second most statistically significant SNP (rs77370934) was located 
within the gene GABRG2 (Gamma-Aminobutyric Acid Receptor Subunit Gamma-2), however, 
there were no other SNPs with a high level of LD in that locus (Figure 3B). 
There were also genome wide statistically significant SNPs within the MBOAT1 gene 
(Membrane Bound O-Acyltransferase Domain Containing 1) and SH2B1 gene (SH2B Adaptor 
Protein 1).  
Figure 4 presents the odds ratio and the 95% confidence interval (95% CI) for the two most 
statistically significantly associated SNPs for the different sub studies of the Rotterdam study 
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and the Go-DARTS population. Except for the RS3 which is the smallest subpopulation, the 
effect directions were concordant between the populations.  
A high level of consistency was observed for the meta-analyses results from both sites using the 
GWAMA and METAL, particularly for the most significantly associated SNPs. 
Discussion: 
Our study describes a large GWAS study investigating SNP variants associated with switching of 
an ACE-inhibitor to an ARB as a marker for ACE inhibitor induced ADRs. All phenotype data for 
this study were derived from clinical settings that incorporate either the prescription data 
system (GoDARTS) or the pharmacy drug dispensing database (Rotterdam study). We found 
statistically significant associations with SNPs located within the genes RBFOX3, GABRG2, 
SH2B1 and MBOAT1. These are novel candidate genes which may play a role in the adverse 
drug reactions to ACE-inhibitors. 
The SNPs showing the strongest association with the phenotype are located on chromosome 17 
within the gene RBFOX3. This is a member of the RBFOX family that in mammals consists of 
three members:  RBFOX1,  RBFOX2 and  RBFOX3. RBFOX3 is expressed specifically in neuronal 
cells. This protein contains an RNA recognition motif that binds specifically to an RNA element, 
UGCAUG and regulates alternative pre-mRNA splicing. Alternative splicing of pre-mRNA is an 
important mechanism for post-transcriptional regulation of gene expression and has 
increasingly been appreciated as a major mechanism to generate diversity of gene products in 
higher eukaryotes [35, 36].  
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The other most strongly associated SNP was located on chromosome 5 within the gene 
GABRG2 which encodes a gamma-aminobutyric acid (GABA) receptor. GABA is the major 
inhibitory neurotransmitter in the mammalian nervous system, where it acts at GABA-A 
receptors. GABA-A receptors are pentameric, consisting of proteins from several subunit 
classes: alpha, beta, gamma, delta and rho [37]. There are several studies proving the effects of 
GABA receptor agonists in decreasing the sensitivity to cough both in animal models and in 
humans. This makes them a possible target for cough treatment [38]. Dicpinigaitis et al showed 
that Baclofen (as a GABA receptor agonist) can supress cough induced by ACE-inhibitors [39]. 
They also proved in a prospective clinical trial that baclofen can inhibit capsaicin-induced cough 
[40]. 
SH2B1 (sarcoma (Src) homology 2 (SH2) B adaptor protein 1) is a member of a family of scaffold 
proteins implicated in signalling downstream of a variety of receptor tyrosine kinases and 
cytokine receptors [41]. Variations in this gene have been reported to be associated with 
obesity [42]; however its role in the abnormal glucose homeostasis has not been proved [43]. 
The significant association of this gene with the intolerance of ACE-inhibitors needs to be 
further investigated because there was no previous report of this gene contributing in cough or 
angioedema.  
MBOAT1 (membrane bound O-acyltransferase domain containing 1) belongs to the superfamily 
of MBOAT that transfer organic compounds, usually fatty acids onto hydroxyl groups of 
membrane-embedded targets [44]. This trans-membrane protein has been reported to be 
involved in developmental processes [45]. 
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The main hypothesized mechanism of ACE-inhibitor induced ADRs (mainly cough and 
angioedema) is stimulation of sensory nerve resulting from the accumulation of inflammatory 
mediators that are normally cleaved by the ACE [3].  This hypothesis has served as the basis for 
candidate gene studies that have focused on variation in inflammatory pathways, however 
findings of those candidate gene studies were replicated inconsistently and the meta-analyses 
of loci that had enough studies, did not find the significant effect for the insertion/deletion 
polymorphism within ACE gene [15]. Hypothesis free GWA studies may lead to finding novel loci 
to be associated with ADRs of ACE-inhibitors. The only available large GWAS on ACE-inhibitor 
induced cough found an association with Kv Channel Interacting Protein 4 (KCNIP4) which is 
predominantly expressed in nervous systems [22]. However the only available GWAS on the 
ACE-inhibitor induced angioedema with 175 ACE-inhibitor induced angioedema cases and 489 
controls could not find any significant association on a genome wide level which could be due 
to the relatively small sample size and lack of the power [21]. Our results suggest that an 
important source of variation may be directly related to the sensory nerves themselves, 
because both GABRG2 and RBFOX3 genes are playing a role in the central and peripheral 
nervous systems as well. These findings are in line with the previous GWAS on ACE-inhibitor 
induced cough [22]. 
This study is a large GWAS on the intolerance of ACE-inhibitors within a population of European 
ancestry. However the direct relevance of our findings with ACE-inhibitor induced ADRs is not 
clear yet and needs to be further investigated, these findings, if replicated in other populations, 
can improve our understanding of the biological mechanism of ACE-inhibitor induced ADRs. 
Furthermore, it will help to identify those patients at high-risk to develop ACE-inhibitor induced 
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ADRs including angioedema, which is a life threatening event. We recently showed that 
approximately 50% of ACE-inhibitor users continue ACE-inhibitors after the first episode of 
angioedema [46]; Identification of those patients at high risk could help physicians guide their 
treatment choice. ACE-inhibitor induced cough is not as life threatening as angioedema but it 
can be misdiagnosed and mistreated which significantly decreases the compliance of patients 
and might finally result in unsuccessful drug therapy [47, 48]. Therefore in the context of 
precision medicine, the ultimate application of these findings within the clinic would be the 
prediction of susceptible patients and treating them with an alternative medication with 
comparable effect such as ARBs [49]. 
An important limitation of this study is defining phenotype based on the electronic medical 
records which can potentially lead to misclassification of cases and controls. However in a 
validation study, the proxy marker for cases showed a positive predictive value of 68.3% for 
probable ACE-inhibitor induced ADRs [23]. This study also cannot detect associations for rare 
SNPs (MAF< 0.01%). The study results are restricted to the European ancestor populations. 
In conclusion, this study used a GWAS to identify SNP variants associated with ACE-inhibitor 
intolerance as a marker of ADRs. We identified SNPs in the genes RBFOX3, GABRG2, SH2B1 and 
MBOAT1 as potential candidates for ACE inhibitor induced ADRs. Due to the fact that this is a 
hypothesis generating study, the functional role of significantly associated genes was not 
investigated; therefore future studies are needed to replicate our findings in addition to the 
epigenetic and molecular studies are needed to explore the functional roles of variations within 
genes reported in this study specifically the GABRG2 gene for which several clinical studies also 
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showed its role in susceptibility to cough [38-40]. The standard clinical criteria have been 
described for ACE-inhibitor induced angioedema [50] and to make it possible to combine results 
it would be good if new genetic association studies would use this standard phenotype in the 
future.    
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FIGURE LEGENDS 
Figure 1. Manhattan plot of genotyped SNPs associated with ace-inhibitor intolerance using an 
additive model adjusted for age and gender. The red line indicates the genome-wide 
significance threshold of alpha=5x10-8. 
Figure 2. A QQ plot for SNP associations from a meta-analysis of GWAS of ACE-inhibitor 
intolerance using an additive model adjusted for age and gender. (Lambda=0.88) 
Figure 3. LocusZoom plot of most strongly associated SNPs from the meta-analysis located in A) 
the region of most significantly associated genes 
A) The RBFOX3 (chromosome 17 centred around SNP rs2061538 (shown in purple). Linkage 
disequilibrium (based on r2 values) with respect to rs2061538 are based on the CEU 
reference population.  
B) The GABRG2 (chromosome 5 centred around SNP rs77370934 (shown in purple). Linkage 
disequilibrium (based on r2 values) with respect to rs77370934 are based on the CEU 
reference population.  
Figure 4. The forest plot from the meta-analyses of most strongly associated SNPs 
GD: GoDARTS, RS: Rotterdam study, CI: confidence interval   
 
 
